Seller record · noom.com

Noom

Recorded September 2026 · Standard v1.1

Fails 3 of 8 criteria. S3, pharmacy identification: Nine pages were read, covering the terms, transparency, privacy and program surfaces, and each describes selected pharmacy partners without naming a facility. 2 more criteria also fail; see the table below.

Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A weight-management subscription whose medical arm prescribes generic, compounded and brand GLP-1 drugs. It publishes an explanation of what a certificate of analysis is and supplies one only on request.

Operating entity Noom, Inc.

Dispositions

Code	Criterion	Disposition	Where it was read
S1	Prescriber requirement	PASS	noom.com/glp-1-access-and-transparency
S2	Prescription gating	PASS	noom.com/survey/dosingPreference
S3	Pharmacy identification	FAIL	noom.com/glp-1-access-and-transparency
S4	Compounding disclosure	FAIL	noom.com/glp-1-access-and-transparency
S5	Analytical documentation	FAIL	noom.com/glp-1-access-and-transparency
S6	Business address	PASS	noom.com/terms-and-conditions-of-use
S7	Price disclosure	PASS	noom.com
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

What was read, where, and on what date, for each disposition in the table above.

S1PASSThe transparency page names Dr. Jeffrey Egler, MD as a double board-certified physician in family medicine and lifestyle medicine, alongside two named pharmacists.Source: noom.com/glp-1-access-and-transparency.

S2PASSThe order path was walked to two clinical survey screens asking dosing and medication preference, both reached before any payment field.Source: noom.com/survey/dosingPreference.

S3FAILNine pages were read, covering the terms, transparency, privacy and program surfaces, and each describes selected pharmacy partners without naming a facility.Source: noom.com/glp-1-access-and-transparency.

S4FAILThe transparency page states that generic, compounded and brand medications are prescribed, and no page read states that a compounded product lacks Food and Drug Administration approval.Source: noom.com/glp-1-access-and-transparency.

S5FAILThe transparency page defines a certificate of analysis and states that patients may request one from their care coordination team, so no document is reachable from the site.Source: noom.com/glp-1-access-and-transparency.

S6PASSThe terms print a street address with a suite number at One Palmer Square in Princeton, New Jersey, given for written notice.Source: noom.com/terms-and-conditions-of-use.

S7PASSThe homepage prints an initial three-week subscription with four weeks of medication from 149 dollars, then 349 dollars per month for the twelve-week subscription after it, and a second tier at 79 dollars then 199 dollars.Source: noom.com.

S8PASSNo letter names the entity in the FDA index, and no action has halted the business; control letter found in the same run.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, brand GLP-1 prescriptions, metformin, behavioral weight-management coaching.

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.